Cibc World Market Inc. reduced its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 14.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 263,219 shares of the company's stock after selling 45,910 shares during the quarter. Cibc World Market Inc.'s holdings in Eli Lilly and Company were worth $304,566,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bank of America Corp DE bought a new stake in Eli Lilly and Company during the second quarter worth about $13,522,666,000. Jupiter Topco LLC acquired a new stake in shares of Eli Lilly and Company during the second quarter worth approximately $4,667,180,000. Corient Private Wealth LP bought a new position in shares of Eli Lilly and Company in the second quarter valued at approximately $764,116,000. BlackRock Inc. raised its stake in shares of Eli Lilly and Company by 1.6% in the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock valued at $81,009,981,000 after acquiring an additional 1,046,558 shares during the last quarter. Finally, State Street Corp boosted its holdings in shares of Eli Lilly and Company by 1.7% in the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company's stock worth $43,438,262,000 after acquiring an additional 605,752 shares in the last quarter. 82.53% of the stock is owned by institutional investors.
More Eli Lilly and Company News
Here's some of the latest news about LLY:
Insider Transactions at Eli Lilly and Company
In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the company's stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the transaction, the executive vice president directly owned 4,137 shares in the company, valued at approximately $5,802,225.24. This represents a 54.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company's stock.
Analyst Ratings Changes
A number of research firms recently commented on LLY. The Goldman Sachs Group restated a "buy" rating and set a $1,413.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, October 20th. HSBC lifted their price objective on Eli Lilly and Company from $850.00 to $940.00 and gave the company a "reduce" rating in a research report on Thursday, September 10th. UBS Group increased their target price on Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the stock a "buy" rating in a report on Friday, October 30th. Bank of America restated a "buy" rating and issued a $1,497.00 target price on shares of Eli Lilly and Company in a research note on Friday, October 30th. Finally, JPMorgan Chase & Co. lifted their price target on Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the company an "overweight" rating in a report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $1,422.00.
Get Our Latest Analysis on Eli Lilly and Company
Eli Lilly and Company Stock Down 1.3%
NYSE:LLY opened at $1,412.63 on Wednesday. The stock's fifty day moving average price is $1,253.71 and its two-hundred day moving average price is $1,114.28. Eli Lilly and Company has a 52-week low of $850.51 and a 52-week high of $1,475.25. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The company has a market cap of $1.33 trillion, a price-to-earnings ratio of 45.85, a P/E/G ratio of 1.71 and a beta of 0.40.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating the consensus estimate of $5.71 by $1.77. The company had revenue of $24.40 billion during the quarter, compared to analysts' expectations of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The business's revenue for the quarter was up 38.6% on a year-over-year basis. During the same period last year, the firm earned $7.02 EPS. On average, analysts anticipate that Eli Lilly and Company will post 35.70 EPS for the current year.
Eli Lilly and Company Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company's payout ratio is currently 22.46%.
Eli Lilly and Company Profile
(
Free Report)
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company's medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Recommended Stories
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.